JPRN-UMIN000004753已完成未知
Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantation - Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantation
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •see Japanese protocol or ask directly to us
研究者
相似试验
已完成
不适用
Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation.Acute lymphoid or myeloid leukemia, acute unclassified leukemia, malignant lymphomaJPRN-UMIN000005319Osaka University22
已完成
1 期
A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.Osteosarcoma Soft tissue sarcoma neuroblastoma Pediatric bone, soft tissue sarcoma at high risk of recurrence.JPRN-UMIN000005312Osaka Universty22
已完成
1 期
A phase I/II study of a WT1-W10 immunotherapy against high-risk MDS and MDS overt AML.High-risk MDS and MDS overt AMJPRN-UMIN000026023Department of Hematology and respiratory Medicine, School of Medicine, Kochi University60
已完成
1 期
Phase I clinical trial of WT1 peptide-based vaccine for the HLA-A*0201 positive patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000000933Department of Cancer immunotherapy, Osaka University Medical School10
已完成
1 期
Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with malignant glioma.Malignant GliomaJPRN-UMIN000003504Department of Cancer immunotherapy, Osaka University Graduate School of Medicine3